Connect with us

Healthcare

Max Healthcare Institute Limited Q4 FY26: Revenue Rises 10% Yoy, Network Operating Ebitda Up 8%

Max Healthcare Institute Limited (MAXHEALTH) reports a 10% YoY revenue rise to ₹2,664 Cr in Q4 FY26, with Network Operating EBITDA up 8% to ₹682 Cr.

shalini shishodia tradealone

Published

on

Max Healthcare Institute Limited Maxhealth Q4 FY26 Results

Max Healthcare Institute Limited (MAXHEALTH) announced its financial and operating results for the fourth quarter and financial year ended March 31, 2026. The company’s network gross revenue rose to ₹2,664 Cr, marking a growth of +10% year-over-year (YoY), driven by an increase in occupied bed days (OBDs). International patient revenue stood at ₹227 Cr, reflecting a growth of +12% YoY and accounting for ~9% of the hospital revenue. Network Operating EBITDA was ₹682 Cr, reflecting a growth of +8% YoY. EBITDA margin for the network stood at 26.8% compared to 27.2% in Q4 FY25 and 26.1% in Q3 FY26. The clinician costs are up by ~230 bps YoY and ~120 bps QoQ, due to an aggressive approach towards hiring clinical talent to support future growth and capacity expansions.

Expansion and New Initiatives

The company has rolled out nearly 20% additional brownfield capacity in the last six months, with another 10% expected by year-end. A 400-bed brownfield tower at Max Smart Super Speciality Hospital was commissioned in April 2026. Similarly, 160-bed brownfield tower at MSSH, Mohali has been fully operationalized. Additionally, 116 beds out of the planned 280-bed brownfield tower at Nanavati Max have been operationalized, with the balance expected to become operational in the next three months.

Strategic Acquisitions and Investments

Max Healthcare consummated the acquisition of a controlling stake of 58.28% in Kalinga Hospital Ltd. (KHL) on May 18, 2026, making it a subsidiary. The board has approved an investment of ~₹1,400 Cr for constructing a 712-bed greenfield hospital at Shaheed Path, Lucknow, which is expected to be commissioned in FY30 to cater to the growing demand for quality healthcare services in Uttar Pradesh.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Max Healthcare Institute Limited

Max Healthcare Institute Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

MAXHEALTH
Healthcare › Medical Care Facilities
APPROACHING RESISTANCE
70
Fundamental
56
Technical
63
Overall

1W +10.19%
1M +23.23%
3M +1.91%
P/E: 72.4 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Max moves sideways over three months, with neither buyers nor sellers taking control. The PEG reaches 3.49. The stock trades on brand and index weight, not on growth. Revenue grows at 21.2% and profits at 21.2% CAGR. Both numbers are exceptional. The stock gains 6.4% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 21.2% and profits at 21.2%. The business is in good shape. Moreover, a stock that does not move despite strong fundamentals often offers better value than one already priced for perfection. Check Fundamentals of Max Healthcare Institute Limited.

BIOCON

Biocon Limited (biocon) Secures Marketing Authorization for Pertuzumab in EU

Biocon Limited (BIOCON) secures EU marketing authorization for Pertuzumab, its first biosimilar under new clinical approach.

abhinav tiwari

Published

on

Biocon Limited Biocon November 2026 Event

Biocon Limited (BSE: 532523; NSE: BIOCON) has announced that the European Commission (EC) has granted marketing authorization for Pebrilzo®, its biosimilar pertuzumab, for the treatment of HER2-positive breast cancer across multiple disease stages in the European Union (EU). This marks a significant regulatory milestone for Biocon, as pertuzumab becomes its fifth oncology biosimilar approved in both Europe and the United States, strengthening its global oncology portfolio.

First Biosimilar Under New Clinical Approach

Biocon’s pertuzumab biosimilar is the first biosimilar to receive EC marketing authorization under the European Medicines Agency’s (EMA) new tailored clinical approach. This milestone follows its positive CHMP opinion on September 17, 2026. Shreehas Tambe, CEO & Managing Director, Biocon, said: “The European Commission’s approval of Pebrilzo®, our pertuzumab biosimilar, the first under its new tailored clinical pathway, marks a significant regulatory milestone for Biocon. With this approval, pertuzumab becomes our fifth oncology biosimilar approved in both Europe and the United States, strengthening our global oncology portfolio and reinforcing our commitment to expanding access to high-quality, affordable biologic therapies for patients with HER2-positive breast cancer.”

Broadening Treatment Options

The approval aims to broaden treatment options for patients with HER2-positive breast cancer while supporting more sustainable healthcare systems in Europe. Extensive orthogonal, state-of-the-art structural and functional analytical characterization, together with comparative clinical pharmacokinetic data, demonstrated that Biocon’s pertuzumab biosimilar is highly similar to the reference product, with no clinically meaningful differences in quality, safety, or efficacy.

As Biocon continues to expand its portfolio and commitment to oncology, this approval underscores its dedication to addressing evolving patient and healthcare needs, particularly in the realm of breast cancer treatment.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Biocon Limited

Biocon Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

BIOCON
Healthcare › Biotechnology
APPROACHING RESISTANCE
52
Fundamental
56
Technical
54
Overall

1W -1.66%
1M +6.46%
3M -12.15%
P/E: 121.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Biocon falls 12.8% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue consistency is the one bright spot — zero dips in five years shows operational resilience. The stock gains 2.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 15.3% and the stock moves sideways over three months. Neither side makes a strong case. The next earnings print will likely break this stock out of its current range. Check Fundamentals of Biocon Limited.

Continue Reading

GLENMARK

Glenmark Pharmaceuticals Limited (glenmark) Announces IND Submission for ISB 2301

Glenmark Pharmaceuticals Limited (GLENMARK) announces IND submission for ISB 2301, a first-in-class multispecific immune cell activator targeting solid tumors.

Pranab Tyagi at TradeAlone

Published

on

Glenmark Pharmaceuticals Limited Glenmark IND Submission

Glenmark Pharmaceuticals Limited (GLENMARK) announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ISB 2301. The focus keyword, Glenmark Pharmaceuticals Limited GLENMARK IND Submission, highlights this significant milestone in the company’s oncology pipeline. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and natural killer (NK) cells.

Advancement in Multispecific Oncology Pipeline

The IND submission marks an important step in advancing Ichnos Glenmark Innovation’s (IGI) multispecific oncology pipeline into clinical development. ISB 2301, engineered using IGI’s proprietary BEAT® Multispecific Platform, combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. This pentaspecific molecule is designed to address biological heterogeneity and immune-suppressive features of solid tumors.

Planned Phase 1 Clinical Trial

IGI plans to initiate a Phase 1 clinical trial evaluating ISB 2301 in patients with solid tumors in 2027. Preclinical results have demonstrated a compelling anti-cancer profile for ISB 2301, showing favorable pharmacokinetic and tolerability profiles in non-human primates. The trial will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of ISB 2301 in patients with advanced solid tumors.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

GLENMARK
Healthcare › Drug Manufacturers - Specialty & Generic
BREAKOUT
78
Fundamental
94
Technical
86
Overall

1W -1.16%
1M +19.72%
3M +13.62%
P/E: 51.5 Cap: Large
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Glenmark rises 12.3% over three months, with buying pressure holding steady. The PEG of 0.77 signals undervaluation relative to growth. It is a potential re-rating candidate. Thin margins at 9.1% leave limited room for error — any demand softness or cost spike hits the bottom line hard. The stock trades at 89% of its 52-week range — near its best levels of the year. Clearly, the market pays a premium for this name. Both the business and the stock move in the right direction. Revenue grows at 13.5%, profits at 66.1%, and the PEG sits at 0.77 — below its growth rate. That combination is rare. Check Fundamentals of Glenmark Pharmaceuticals Limited.

Continue Reading

Drug Manufacturers - General

Sai Parenterals Limited (saiparent) Acquires Majority Stake in Bion Therapeutics’ Prescription Business

Sai Parenterals Limited (SAIPARENT) announces acquisition of Bion Therapeutics’ prescription business, adding 16 brands and enhancing market presence.

Pranab Tyagi at TradeAlone

Published

on

Sai Parenterals Limited Saiparent November 2026 Acquisition

Sai Parenterals Limited (NSE: SAIPARENT) has announced a strategic move to acquire a majority stake in Bion Therapeutics India Private Limited (Bion), a Hyderabad-based branded formulations prescription business company. This acquisition, executed through its wholly owned subsidiary SP Analytics Private Limited, is expected to be finalized before the end of this month. The transaction will be an all-cash deal, significantly strengthening Sai Parenterals’ presence in India’s prescription market.

Strategic Benefits

The acquisition of Bion Therapeutics will add 16 established brands and around 250 field staff to Sai Parenterals, enhancing its competitive position in the domestic pharmaceutical landscape. Bion’s extensive infrastructure provides immediate access to a broader market, integrating with Sai Parenterals’ manufacturing capabilities to ensure assured supply, consistent quality, and improved margins.

Operational Integration

Bion’s portfolio, currently manufactured by third parties, will progressively transfer to Sai Parenterals’ accredited facilities, which hold TGA-Australia and WHO-GMP accreditations. This move will allow Bion’s brands to leverage Sai Parenterals’ development pipeline and Noumed’s dossier library, offering a wider portfolio to its existing doctor coverage. The critical-care injectable facility, SAICRITI, due for completion in August 2027, will provide a route into hospital and critical-care segments for Bion’s injectable brands.

Forward-Looking Vision

Commenting on the agreement, Mr. Anil Kumar Karusala, Chairman and Managing Director, Sai Parenterals Limited, emphasized the strategic importance of this acquisition in converting development capability into branded revenue. The value flows in both directions, with Bion’s portfolio transferring to Sai Parenterals’ facilities and Sai Parenterals’ development pipeline broadening Bion’s market offerings. Further particulars of the transaction will be disclosed at the appropriate stage.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Sai Parenterals Limited

Sai Parenterals Limited belongs to the › sector. Here’s a quick read on where the business and the stock stand today.

SAIPARENT
Healthcare › Drug Manufacturers - General
CONSOLIDATING DOWN
72
Fundamental
66
Technical
70
Overall

1W -0.83%
1M +3.88%
3M -9.1%
P/E: 89 Cap: Small
AI-Powered Analysis • TradeAlone
Download the App for in-depth analysis of this stock

Sai falls 8.2% over three months and has not found a floor yet. Razor-thin margins below 5% make profitability extremely vulnerable — this business needs scale or pricing power urgently. Revenue grows at 57.9% and profits at 48.3% CAGR. Both numbers are exceptional. The stock gains 3.9% in the last month, recovering from the three-month slide. However, it is too early to call this a confirmed reversal. Revenue grows at 57.9% and profits at 48.3% CAGR, with D/E of 0.00. Meanwhile, the stock dips 8.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Sai Parenterals Limited.

Continue Reading

Trending

Exit mobile version